Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

9.100 -0.180 (-1.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 Next >
Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Announces Appointment of Karen-Leigh Edwards as Senior Vice President of Technical Operations
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Updates Monthly In-Market Unit Sales of DEXTENZA® Billable Inserts
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ to Present at the H.C. Wainwright Ophthalmology Virtual Conference
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Reports Second Quarter 2021 Financial Results and Business Update
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Announces First Patient Dosed in U.S.-based Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet Age-Related Macular Degeneration
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ To Report Second Quarter 2021 Financial Results
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ To Present Clinical Data at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Announces Second Quarter 2021 Preliminary Net Product Revenue of $11.7 Million
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dry Age-Related Macular Degeneration
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Reports First Quarter 2021 Financial Results and Business Update
From Ocular Therapeutix, Inc.
Via Business Wire
CORRECTING and REPLACING Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ Fulfills Post-Marketing Approval Requirements for ReSure® Sealant
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
From Ocular Therapeutix, Inc.
Via Business Wire
Ocular Therapeutix™ To Report First Quarter 2021 Financial Results
From Ocular Therapeutix, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.